Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Clinical trial NCT02024087 · COMPLETED

Trial details

NCT number

NCT02024087

Sponsor

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA

Status

COMPLETED

Phase

Phase 1, Phase 2

Study type

INTERVENTIONAL

Start date

2014-08-04

Primary completion

2017-07-05

Enrollment

21

View on ClinicalTrials.gov